Drug updated on 10/21/2024
| Dosage Form | Injection (subcutaneous; 3 mg/1.5 mL [2 mg/mL], 40 mg/mL) |
| Drug Class | GPRC5D-directed CD3 T-cell engagers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1-2]
- The overall response rate (ORR) for BCMA-targeting bispecific antibodies (BSABS) in treating relapsed refractory multiple myeloma (RRMM) across 13 studies ranged from 25% to 100%, with complete response/stringent complete response (CR (Complete Response)/sCR) between 7% and 38%, very good partial response (VGPR) from 5% to 92%, and partial response (PR) from 5% to 14%.
- For non-BCMA-targeting agents studied across five trials, the ORR ranged from 60% to 100%, with CR/sCR between 19% and 63% and VGPR between 21% and 65%, indicating generally higher efficacy compared to BCMA-targeting agents.
- The review focuses on patients with RRMM but does not provide further differentiation in effectiveness based on specific population types or subgroups.
- Common adverse events associated with bispecific antibodies (BSABS) in patients with relapsed refractory multiple myeloma (RRMM) included cytokine release syndrome (CRS) occurring in 17-82% of patients, anemia in 5-52%, neutropenia in 12-75%, and thrombocytopenia in 14-42%.
- The safety profile of BsAbs was generally considered good within the RRMM cohort, with no specific significant safety concerns or adverse effects reported for particular population types or subgroups.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Talvey (talquetamab-tgvs) Prescribing Information. | 2023 | Janssen Biotech, Inc., Horsham, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma. | 2024 | The Annals of Pharmacotherapy |
| The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review | 2023 | Antibodies |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. | 2023 | Journal of the National Comprehensive Cancer Network |